News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Multiple Myeloma Research Consortium and Synta Pharmaceuticals Announce Initiation of Ganetespib Clinical Trial in Multiple Myeloma



4/10/2012 10:18:07 AM

NORWALK, Conn. & LEXINGTON, Mass.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals (NASDAQ: SNTA), as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADEĀ®) for the treatment of relapsed multiple myeloma.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES